tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins

PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins

Written by Ι Stock Market Media — January 27, 2020

PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC), has passed each of the U.S. Food and Drug Administration’s (FDA) required “release tests” for safety and functionality.  With a clinical trial product that has proven to be safe and functional, PharmaCyte is now “on-the-clock” for its submission of an Investigational New Drug ...

Read More →
0

GBT Technologies Transforming the Future Healthcare AI Market

GBT Technologies Transforming the Future Healthcare AI Market

Written by Ι Stock Market Media — January 16, 2020

GBT Technologies, Inc. (OTC PINK: GTCH) (GBT) is among a handful of companies that are developing Artificial Intelligence (AI) and Internet of Things (IoT) solutions that are expected to transform the future of the healthcare industry.  Both segments of the industry, AI and IoT, are growing exponentially, and GBT’s technology is ideally positioned to succeed in this burgeoning marketplace.

GBT will grow its footprint in the industry with its “Avant! AI” (Avant!) technology, a ...

Read More →
0

GBT Technologies’ AI Engine Improving Microchip Production and Creating Expert Smart Apps

GBT Technologies’ AI Engine Improving Microchip Production and Creating Expert Smart Apps

Written by Ι Stock Market Media — December 3, 2019

GBT Technologies, Inc. (OTC PINK: GTCH) (GBT) is steadily growing its footprint in the high-tech space while also expanding its already strong portfolio of technologies that continue to increase the company’s position in the industry.  GBT is segmented into 5 different areas of growth, but its work in the artificial intelligence or AI industry continues to be the company’s central focus, and its AI engine, “Avant! AI,” could prove to be an industry-leading ...

Read More →
0

PharmaCyte Biotech’s Release Testing Last Critical Event Before Submission of Investigational New Drug Application

PharmaCyte Biotech’s Release Testing Last Critical Event Before Submission of Investigational New Drug Application

Written by Ι Stock Market Media — November 12, 2019

PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can submit an Investigational New Drug application (IND) to the U.S. FDA.  PharmaCyte’s IND application will request permission from the FDA to conduct a Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).  With the FDA’s approval to begin a clinical trial, PharmaCyte’s opportunities for funding improve dramatically.

PharmaCyte has already ...

Read More →
0

GBT Technologies Competing in $4 Trillion AI Market with Disruptive Technology

GBT Technologies Competing in $4 Trillion AI Market with Disruptive Technology

Written by Ι Stock Market Media — November 8, 2019

GBT Technologies, Inc. (OTC PINK: GTCH) has a vast portfolio of intellectual property that spans both the Artificial Intelligence (AI) and Internet of Things (IoT) markets.  But the company’s central focus is on a technology called “Avant! AI”—a technology that could become commonplace in both businesses and households worldwide.  It is the extremely promising potential of Avant! that has GBT Technologies (GBT) ideally positioned to compete in what Gartner, a leading research and ...

Read More →
0

PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial

PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial

Written by Ι Stock Market Media — October 28, 2019

PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable future.  The company is closer than ever to its upcoming Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) that could give patients a new lease on life by shrinking their tumors enough so that the tumors can be removed surgically.  It is an outcome that would ...

Read More →
0
Page 1 of 33 12345...»
ContactUs.com ContactUs.com